Article Text
PDFFiller
Misoprostol in a topsyturvy world
Statistics from Altmetric.com
sir
In the January 4 issue of the New England Journal of Medicine three articles appeared on the unapproved use of Misoprostol (Cytotec), which raise an interesting ethical question. The synthetic prostaglandin analogue, Misoprostol, has been successfully used by obstetricians and gynaecologists for a number of years for the induction of a medical abortion in the first or second trimester, for the induction of labour, and for the prevention of postpartum haemorrhages.1 Strangely enough the pharmaceutical company which produces and markets the drug, Searle, …
Read the full text or download the PDF:
Other content recommended for you
- Misoprostol knowledge and distribution in Mexico City after the change in abortion law: a survey of pharmacy staff
- A cross-sectional examination of conflict-of-interest disclosures of physician-authors publishing in high-impact US medical journals
- Quality assessment of patient leaflets on misoprostol-induced labour: does written information adhere to international standards for patient involvement and informed consent?
- Medical abortion: the hidden revolution
- Self-managed abortion in urban Haiti: a mixed-methods study
- Oral misoprostol for induction of labour at term: randomised controlled trial
- Covid-19: How independent were the US and British vaccine advisory committees?
- Misoprostol-augmented induction of labour for third trimester fetal demise in a patient with prior hysterotomies
- Rosiglitazone, marketing, and medical science
- Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making